[Famciclovir treatment of patients with chronic hepatitis B virus infection].

Abstract

OBJECTIVE:

To evaluate the effects of famciclovir treatment of patients with chronic hepatitis B virus (HBV) infection.

METHODS:

Eighty-nine patients with chronic HBV infection were randomly divided into three groups. Thirty-two patients were treated with famciclovir, 29 patients and 28 patients with chronic HBV infection were treated with interferon (IFN) alpha and lamivudine, respectively, as the control.

RESULTS:

The serum HBV DNA became negative after treatment in 40.62% (13/32) of patients treated with famciclovir, 37.93% (11/29) of patients treated with IFN alpha, and 67.90% (19/28) of patients treated with lamivudine. The rate of serum HBeAg loss for the three groups were 21.88% (7/32), 41.38% (12/29) and 21.43% (6/28), respectively. The average time for patients to become serum HBV DNA negative was 1.3 months.

CONCLUSIONS:

Famciclovir is an effective and safe nucleoside drug for the treatment of patients with chronic HBV infection.

• Authors: Li Li, Qing Shao, Jian Zhang, Dong Ji
• Journal: Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology (Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi) Vol. 16 Issue 4 Pg. 390-1 (Dec 2002) ISSN: 1003-9279 [Print] China
• PMID: 12665916 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiviral Agents
• Interferon-alpha
• Lamivudine
• 2-Aminopurine
• Famciclovir

Topics

• 2-Aminopurine (analogs & derivatives, therapeutic use)
• Adolescent
• Aged
• Antiviral Agents (therapeutic use)
• Famciclovir
• Female
• Hepatitis B virus (genetics)
• Hepatitis B, Chronic (drug therapy)
• Humans
• Interferon-alpha (therapeutic use)
• Lamivudine (therapeutic use)
• Male
• Middle Aged
• Treatment Outcome